Sally Gardner, the award-winning author of children's books, has opened up about a hidden struggle that nearly derailed her life. After her career took off in her 40s, selling millions of copies and winning major literary prizes, she found herself trapped in a cycle of compulsive spending she couldn't explain. Lavish purchases, from expensive bathtubs to designer art, became a source of secret shame and mounting debt.
The turning point came when Gardner connected her behavior to a medication she had been taking for years. Prescribed dopamine agonists to treat her restless legs syndrome, a condition causing an uncontrollable urge to move, especially at night, the drug initially brought immense relief. However, she now understands it was the catalyst for her impulsive spending, a side effect she was never warned about by her doctor.
Her story is not isolated. A BBC investigation has uncovered hundreds of similar cases where patients on dopamine agonists, used for conditions like Parkinson's and restless legs syndrome, developed severe behavioral changes. These include compulsive shopping, gambling, and hypersexuality, often leading to ruined finances, broken relationships, and profound personal distress.
Gardner's experience highlights a particularly insidious aspect of shopping addiction. Experts note that unlike more visible compulsions, excessive online purchasing can go unnoticed for longer, sometimes misinterpreted as generosity rather than a pathological behavior. Gardner herself bought the same pair of shoes five times and multiple beds for her dog, all while her debt spiraled.
The consequences were severe. Gardner was forced to sell her London home and move to a smaller apartment, only to spend tens of thousands more on its decoration. She estimates the financial damage at around £500,000. The emotional toll was equally heavy, leaving her feeling as though her life had been hijacked.
It was only after listening to a BBC podcast that Gardner finally made the connection. The realization brought a mix of relief at having an explanation and anger over the years lost. She now advocates for greater awareness and monitoring of patients prescribed these powerful medications.
In response to these findings, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing its warnings on dopamine agonists. The agency emphasizes that all medicines carry risks and that patients should be informed about potential side effects, including changes in behavior.
Gardner's courageous disclosure serves as a stark warning. It underscores the critical need for patients and doctors to have open conversations about the full spectrum of a medication's potential impacts, ensuring that a treatment for one condition does not inadvertently create another devastating problem. Based on reporting from g1.